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Objective. *e KOSMOS study, a multicenter, randomized, double-blind, placebo-controlled trial, investigated the effects and safety
of kamishoyosan (TJ-24), a traditional Japanese medicine, in the treatment of climacteric disorder.Methods. Japanese women with
climacteric disorder were administered a placebo during a 4-week run-in period, after which they were classified as placebo re-
sponders (R group) if their score on the modified Questionnaire for the Assessment of Climacteric Symptoms in Japanese Women
(m-QACS) with excitability and irritability as the primary outcome improved by≥ 3 points and as placebo nonresponders (NR
group) otherwise. Members of the NR group were randomly allocated to receive either TJ-24 or placebo. After 12 weeks, their
m-QACS scores, anxiety and depression, sleep, and overall quality of life (QOL) were compared. Results.*e TJ-24 and placebo arms
in the NR group included 20 patients each. *e change in the m-QACS scores of members of the NR group for excitability and
irritability at 12 weeks versus baseline was –3.1± 1.7 in the TJ-24 arm, a significant decrease, but compared with –2.7± 2.2 in the
placebo arm, no significant difference was between two arms. However, the proportion of participants whose score improved by ≥3
points was significantly higher in the TJ-24 arm. In the subgroup analysis of premenopausal women, the changes in the score for
excitability and irritability were significantly larger in the TJ-24 arm.*e incidence of adverse drug reactions or adverse events did
not differ between the two arms, and no serious events were reported. Conclusion. Although no significant difference was
identified for the primary outcome, a significantly higher proportion of patients who received TJ-24 displayed improvement.
Its high level of safety and effects on excitability and irritability in premenopausal women suggest that TJ-24 may be a
useful treatment.
1. Introduction
Climacteric disorder is a major factor in diminishing quality
of life (QOL) starting in perimenopause, and managing its
symptoms is an urgent task. Hormone therapy (HT) to
augment the level of estrogen, which decreases because of
menopause, is known to be effective, and this treatment is
provided also in Japan [1]. However, the combined estrogen-
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progestogen therapy arm of the 2002 Women’s Health
Initiative study was stopped mainly because of an increased
risk of breast cancer [2], HT has been negatively viewed, and
nonhormonal therapies have gained popularity. *e treat-
ments used in Western countries include selective serotonin
reuptake inhibitors and cognitive behavioral therapy [3].
Measures are also required to help perimenopausal women
whose estrogen levels remain close to normal.
In Japan, traditional Japanese medicine (Kampo ther-
apy) has long been practiced [4, 5]. Kampo therapy uses
combinations of crude natural drugs, and compliance is
high. One such formulation, kamishoyosan (TJ-24), has
been reported to improve neuropsychiatric symptoms [6, 7],
vasomotor symptoms [6], and sleep disturbance [8] in pa-
tients with climacteric disorder, and it is widely used. Un-
fortunately, previous studies have failed to provide evidence
of its efficacy [9].
*erefore, we previously conducted a double-blind,
randomized, placebo-controlled trial of the efficacy of TJ-24.
In that study, although TJ-24 was associated with significant
improvements in the frequency of hot flashes, depression,
anxiety, and QOL after the start of treatment, no significant
difference was identified between the TJ-24 and placebo
arms [10]. We concluded that Kampo drug administration
elicits a strong placebo effect on menopausal symptoms and
that studies focusing on individual symptoms are required.
From these results, we conducted a new double-blind,
randomized, parallel-group comparative study to investigate
the efficacy and safety of TJ-24, termed the kamishoyosan’s
effects on some menopausal symptoms (KOSMOS) study.
*is study adopted a design that included a run-in period of
placebo administration and stratification of participants into
placebo responders and nonresponders to minimize the
placebo effect. In addition, the symptoms observed in cli-
macteric disorder were also subdivided to investigate the
effect of TJ-24 in detail; particularly, we focused on excit-
ability and irritability. *e results of KOSMOS study are
reported.
2. Subjects and Methods
2.1. Participants. Japanese women aged 40–60 years who
complained of climacteric disorder were recruited for the
study from the authors’ institutions between April 2016 and
March 2018. Climacteric disorder was assessed by con-
verting severity scores on the modified Questionnaire for the
Assessment of Climacteric Symptoms in Japanese Women
(m-QACS) [11] to a 0–10 numerical rating scale, and par-
ticipants were selected from women with an excitability and
irritability score of ≥5 points plus a score of ≥5 points for
either sleep disturbance or vasomotor symptoms (i.e., any
one of hot flashes, sweating, difficulty in sleeping, or waking
up at night).
*e exclusion criteria were severe intestinal fragility,
poor appetite, nausea or vomiting, serious psychiatric or
neurological disorder, existing allergy to Kampomedication,
serious comorbidity such as liver disease, heart disease,
hematological disease, or malignancy, or any other reason
that disqualified the individual concerned in the judgment of
the investigator. *e concomitant use of female hormones,
autonomic neuromodulators, anxiolytics, psychotropics,
hypnotics, antidepressants, kallidinogenase formulations, or
other Kampo medications was prohibited. Individuals who
had used any of these drugs within the previous 4 weeks
before enrollment were also excluded. *e concomitant use
of over-the-counter supplements was permitted, but par-
ticipants were asked not to start taking a new supplement or
to change the dose or administration method during the
study period.
2.2. Study Protocol. As presented in Figure 1, after informed
consent was obtained, participants were administered a
placebo for a 4-week run-in period. At the end of these 4
weeks, they were classified as placebo responders (R group)
if their excitability and irritability score improved by≥ 3
points and as placebo nonresponders (NR group) otherwise.
Blinding and randomization were performed by the in-
vestigator responsible for test drug allocation, who used the
permuted block method to allocate subjects into the R and
NR groups to receive either TJ-24 or an externally indis-
tinguishable placebo. Allocation was performed in the order
in which participants were enrolled in each institution.
*is study was performed under the Declaration of
Helsinki, and the study protocol was approved by the In-
stitutional Review Board of each institution (IRB project No.
at Tokyo Dental College, Kindai Univ., Tokyo Medical and
Dental Univ., and Hirosaki Univ. were TJ-24-4-1, IV-3-72,
2016–0001, and Rin-1, respectively). *is study is registered
in JAPIC Clinical Trials Information in Japan (JapicCTI-
No.163215), and a summary of this study is available on the
JAPIC Clinical Trials Information website (https://www.
clinicaltrials.jp/cti-user/trial/Show.jsp).
2.3. Sample Size. *e target enrollment was 40 participants
in the NR group and 20 in the R group, and enrollment was
concluded when 40 participants had been enrolled in the NR
group. *e rationale for this sample size was based on the
assumption that a difference in the changing of the m-QACS
score between the TJ-24 and placebo arms in the NR group
would be ≥4. *erefore, if the standard deviation was 4 and
the participants were allocated to the TJ-24 and placebo
arms in a 1 :1 ratio, the sample size required to achieve a
detection rate of 80% in a two-tailed t-test with p � 0.05
would be 17 participants in each arm. To account for
dropouts, the target enrollment for the NR group was set at
40, with 20 participants each receiving TJ-24 and the pla-
cebo. In a study conducted by Plotnikoff et al., the hot flash
score improved by <30% after 12 weeks of placebo treatment
in 19 of 29 patients, who were thus deemed nonresponders
[9], and it was considered that the ratio between the NR and
R groups should be 2 :1. Accordingly, the target enrollment
was set at 40 participants in the NR group and 20 in the R
group.
2.4. Drugs Used. Subjects were administered either
kamishoyosan (Tsumura-Kampo Kamishoyosan Extract
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Granules, Tsumura and Co., Tokyo, Japan) or a placebo
having a similar appearance to kamishoyosan, supplied by
Tsumura and Co., at a dose of 7.5 g/day divided into three
portions and taken before or after each meal. Kamishoyosan
was used as a powdered extract obtained by spray-drying a
hot extract mixture of the following 10 crude herbs: 13.3%
Bupleuri Radix (Bupleurum falcatum), 13.3% Paeoniae
Radix (Paeonia lactiflora), 13.3% Atractylodis Rhizoma
(Atractylodes ovate), 13.3% Angelicae Radix (Angelica
acutiloba), 13.3% Hoelen (Poria cocos), 8.9% Gardeniae
Fructus (Gardenia jasminoides), 8.9% Moutan Cortex
(Paeonia suffruticosa), 6.7% Glycyrrhizae Radix (Glycyrrhiza
uralensis), 4.4% Zingiberis Rhizoma (Zingiber officinale),
and 4.4% Menthae Herba (Mentha arvensis). *e placebo
formulation included lactose hydrate, magnesium stearate,
cornstarch, dextrin, iron sesquioxide, yellow no. 4 aluminum
lake, blue no. 1 aluminum lake, and caramel.
2.5. Measured Values. Climacteric disorder symptoms were
evaluated using a numerical rating scale of the m-QACS
[11]. *is self-administered questionnaire assesses the se-
verity of 21 symptoms on a scale of 0 to 10, with 0 being least
severe, instead of 0 to 3 in the original version. *e scores
were checked at each visit, namely, weeks –4, 0 (baseline), 4,
8, and 12. In addition, psychiatric symptoms, namely,
anxiety and depression, were assessed using the Hospital
Anxiety and Depression Scale (HADS) [12], and sleep
disturbance was assessed using the Pittsburgh Sleep Quality
Index (PSQI) [13]. Overall QOL was assessed using the SF-8
[14]. *e scores of these questionnaires were checked at
Weeks 0 (baseline), 4, 8, and 12. Variations of ±1 week were
permitted for the investigations at each time point.
To assess safety, the participants underwent two blood
tests during the trial, first during the run-in period and then
after the 12 weeks of treatment. *e major adverse drug
reactions to TJ-24 listed in its package insert on the basis of
current knowledge are pseudoaldosteronism, myopathy,
hepatic impairment, and jaundice, and these were investi-
gated by performing a complete blood count and testing for
liver function, kidney function, and electrolytes levels in
blood. A physical examination was performed at each
hospital visit, during which blood pressure, weight, and
edema were checked, and adverse events were reported at
the time of occurrence.
2.6. Primary and Secondary Outcomes. *e primary out-
come was the change of the m-QASC score for excitability
and irritability in the NR group between the start of the
treatment period (week 0) and week 12. Secondary outcomes
were the changes in scores for all 21 items in m-QACS,
HADS, PSQI, and SF-8 between week 0 and weeks 4, 8, and
12, and subgroup analyses were also conducted with par-
ticipants stratified according to the baseline menopausal
status (≧12 months amenorrhea was defined as menopause,
and others were defined as premenopause), body mass index
(BMI), the duration of climacteric disorder, and prior
hysterectomy/oophorectomy.
2.7. Adverse events and Safety. Safety and tolerability were
assessed by recording all adverse events and abnormal
clinical laboratory test results. Adverse events were defined
as “adverse drug reactions” if a causal relationship with the
study drug could not be eliminated.
2.8. Statistical Analysis. Baseline characteristics were in-
vestigated using Student’s t-test, Fisher’s exact test, or
Wilcoxon’s rank-sum test, depending on the nature of the
data. Data obtained from the changes of the m-QACS score,
HADS score, PSQI score, and SF-8 score were used to
calculate summary statistics for scores at each time point and
changes versus baseline. Wilcoxon’s signed-rank test was
used to analyze the changes in scores from baseline at each
time point in each treatment arm, and differences between
















Figure 1: Study design.
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tested using Wilcoxon’s rank-sum test. Comparisons be-
tween the arms concerning the distribution of changes in the
excitability and irritability score were performed using
Fisher’s exact test.
*e full analysis set (FAS) for the efficacy assessment
included participants enrolled in this study, excluding those
missing data required for the efficacy analysis and those who
clearly failed to take their allocated test drug.
*e safety analysis set included all patients who com-
pleted the study without restriction.
Adverse events were listed as the lowest-level terms in the
ICH Medical Dictionary for Regulatory Activities/Japanese
(MedDRA/J) version 21.0. *ey were tabulated by preferred
term and classified by system organ class. *e rates of adverse
events, adverse drug reactions, serious adverse events, and
serious adverse drug reactions in the safety analysis set were
tabulated by stratum and arm, and the 95% confidence in-
tervals for their rates were calculated, with Fisher’s exact test
used for comparisons between arms. Analyses were con-
ducted using SAS 9.4 software (SAS Institute Inc., Cary, NC,
USA), with p< 0.05 regarded as significant.
3. Results
3.1. Status of Placebo Response and Baseline Characteristics in
Each Arm. Figure 2 presents the allocation of participants in
this study. Of the 55 individuals enrolled in the study, two
withdrew before randomization (withdrawal of consent and
failure to attend the study visit) and 53 participants were thus
randomly allocated. None of the allocated participants missed
data required for efficacy analysis, and the FAS accordingly
consisted of these 53 individuals, as did the safety analysis set.
In the assessment at the end of the 4-week run-in period,
40 participants (75.5%) were classified in the NR group, and
the R group included the remaining 13 participants (24.5%).
Participants in both groups were randomized to receive
either TJ-24 or placebo. Table 1 presents the baseline
characteristics of each arm. In the NR group, the score for
waking up at night was significantly different between
participants in the TJ-24 and placebo arms, but there were
no other significant differences.
3.2. Effect of TJ-24 on Different Complaints in the Placebo NR
Group. *e effect of TJ-24 on participants in the NR group,
who were considered less susceptible to the placebo effect,
was investigated. As illustrated in Table 2, the changes of the
excitability and irritability score during the treatment pe-
riod, the primary outcome, decreased significantly by
–3.1± 1.7 in the TJ-24 arm versus baseline. However, the
score decreased by –2.7± 2.2 in the placebo arm, with no
significant difference between the two arms (p � 0.519).
*ere was also no significant difference between the TJ-24
and placebo arms in the rate of other common menopausal
symptoms including hot flashes, sweating, and sleep dis-
turbance-related complaints (Table 2), and this was also the
case for other symptoms.
Regarding secondary outcomes, an investigation of
psychiatric symptoms, as assessed using HADS, revealed no
significant difference over the treatment period between the
TJ-24 and placebo arms. In particular, the anxiety score
decreased by –0.5± 1.3 in the TJ-24 arm and by –0.7± 2.0 in
the placebo arm, and the depression score increased by
0.5± 1.5 in the TJ-24 arm and by 0.6± 1.8 in the placebo arm.
An investigation of sleep disturbance as assessed using PSQI
also found no significant difference in the change of the total
score over the treatment period between the TJ-24 and
placebo arms (–1.6± 1.5 in the TJ-24 arm vs. –2.4± 2.3 in the
placebo arm), and no significant difference was observed
concerning the time required to fall asleep or the duration of
sleep. An assessment of QOL using the SF-8 also found no
significant difference between the TJ-24 and placebo arms in
either the physical component summary score (3.0± 6.0 in
the TJ-24 arm vs. 2.4± 6.6 in the placebo arm), or the mental
component summary score (1.9± 7.9 in the TJ-24 arm vs.
4.0± 8.5 in the placebo arm).
To investigate whether baseline characteristics altered
the effect of TJ-24, participants were classified by meno-
pausal status, BMI, the duration of climacteric disorder, and
prior hysterectomy/oophorectomy. Of these, menopausal
status altered the effect on several symptoms. As presented
in Table 3, in premenopausal women, the changes of the
excitability and irritability score were significantly greater in
the TJ-24 arm than in the placebo arm (–3.6± 1.5 vs.
–2.2± 2.1), suggesting that TJ-24 may be effective against
excitability and irritability in women who have yet to un-
dergo menopause. In postmenopausal women, there was no
significant difference in the excitability and irritability score
between the groups, whereas the changes in the scores for
hot flashes and sweating were significantly larger in the
placebo arm than in the TJ-24 arm.*ere were no significant
differences for any other baseline characteristics.
In line with the results in the NR group, there were no
significant differences concerning various different com-
plaints between the TJ-24 and placebo arms in the R group.
3.3. Detailed Analysis of the Effect of TJ-24 on Excitability and
Irritability. To analyze the placebo effect in detail, the effects
of TJ-24 and the placebo on excitability and irritability were
investigated in a post hoc analysis. Figure 3(a) presents the
distribution of changes in the excitability and irritability
score over the treatment period. In the TJ-24 arm, the
change was almost evenly distributed, peaking at –3.
Contrarily, in the placebo arm, the distribution had double
peaks at –1 and –5. Using thresholds of score changes of ≥3
for improvement and change of 1 or 2 for slightly im-
provement, the proportion of participants with improve-
ment was 70% in the TJ-24 arm and 45% in the placebo arm,
representing a significant difference (Figure 3(b)).
3.4. Safety of TJ-24 Administration. An analysis of the FAS
found that 17 adverse events occurred in 11 participants and
six adverse drug reactions occurred in four participants in
the TJ-24 arm, including six cases of the common cold or
influenza, and one case each of vomiting, diarrhea, cuta-
neous pruritus, and herpes labialis. In the placebo arm, 11
adverse events occurred in seven patients, and two adverse
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Figure 2: Allocation of study participants.
Table 1: Baseline characteristics of the study participants.
Placebo nonresponder (NR) Placebo responder (R) NR vs. R
TJ-24 (n� 20) Placebo (n� 20) P value TJ-24 (n� 7) Placebo (n� 6) p value p value
Age (years) 51.5± 2.6 51.2± 3.4 0.798a 52.1± 2.5 50.7± 1.4 0.231a 0.881a
BMI (kg/m2) 21.0± 1.9 22.9± 4.2 0.072a 24.4± 2.6 22.6± 3.0 0.294a 0.126a
Time from LMP (days) 750.6± 889.7 708.0± 946.9 0.884a 498.3± 342.5 232.3± 136.6 0.103a 0.175a
Menopausal status
Premenopausal 11 (55.0%) 11 (55.0%) 1.000 b 2 (28.6%) 5 (83.3%) 0.103 b 1.000bPostmenopausal 9 (45.0%) 9 (45.0%) 5 (71.4%) 1 (16.7%)
Disease duration (months) 26.3± 20.3 21.8± 19.7 0.500a 27.0± 18.3 11.8± 10.0 0.099a 0.521a
Excitability and irritability score 7.2± 1.3 6.9± 1.4 0.625c 3.7± 1.8 3.8± 1.9 1.000c <0.001c
Hot flashes score 5.7± 2.2 6.0± 2.2 0.582c 5.7± 2.5 4.2± 2.1 0.184c 0.211c
Sweating score 6.3± 2.1 6.7± 2.2 0.534c 6.3± 0.8 4.2± 2.4 0.069c 0.048c
Difficulty in sleeping score 5.3± 2.6 5.4± 2.7 0.870c 4.1± 2.3 4.2± 2.9 0.885c 0.189c
Waking up at night score 4.6± 2.6 6.4± 2.2 0.024c 6.3± 1.9 3.8± 2.9 0.131c 0.723c
aStudent’s t-test. bFisher’s exact test. cWilcoxon’s rank-sum test.
Table 2: Changes of scores in the modified questionnaire for climacteric symptoms in Japanese women (placebo nonresponder group).
Mean changes of scores in the modified questionnaire for
climacteric symptoms in Japanese women
Placebo nonresponder (NR)
TJ-24 (n� 20) Placebo (n� 20) p value
Excitability and irritability −3.1± 1.7 −2.7± 2.2 0.519
Hot flashes −1.9± 2.4 −1.9± 3.0 0.816
Sweating −1.6± 2.7 −1.6± 2.9 0.989
Difficulty in sleeping −1.9± 2.1 −1.9± 2.3 0.923
Waking up at night −1.2± 2.8 −1.8± 2.5 0.595
Data are the mean changes from baseline of climacteric symptoms at week 12 in the placebo nonresponder group.
Table 3: Subgroup analysis of changes of scores in the modified questionnaire for climacteric symptoms in Japanese women (placebo
nonresponder group).
Mean changes of scores in the modified
questionnaire for climacteric symptoms in
Japanese women
Premenopausal Postmenopausal
TJ-24 (n� 11) Placebo (n� 11) p value TJ-24 (n� 9) Placebo (n� 9) p value
Excitability and irritability −3.6± 1.5 −2.2± 2.1 0.046 −2.3± 1.7 −3.2± 2.3 0.323
Hot flashes −2.2± 2.6 −0.2± 2.7 0.116 −1.4± 2.2 −3.9± 1.9 0.032
Sweating −2.4± 3.4 −0.5± 3.2 0.129 −0.7± 1.3 −2.8± 2.0 0.039
Difficulty in sleeping −1.9± 2.2 −0.9± 1.8 0.363 −1.9± 2.0 −3.1± 2.4 0.416
Waking up at night −0.5± 3.1 −1.2± 2.5 0.894 −1.9± 2.3 −2.6± 2.5 0.533
Data are the mean changes from baseline of climacteric symptoms at week 12 in the placebo nonresponder group.
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drug reactions occurred in two patients, including four cases
of the common cold, two cases of constipation, and one case
each of diarrhea and cutaneous pruritus. No event was
serious. *ere was no significant difference in the incidences
of either adverse drug reactions or adverse events between
the TJ-24 and placebo arms in the NR and R groups. *ere
were no abnormal results in the blood testing, excluding one
case of slight hyperkalemia in a patient who received TJ-24.
4. Discussion
In Japan, HT is not widely used to treat climacteric disorder.
Conversely, because of its safety, Kampo medication is more
widely used, and that drug adherence is high. *e medi-
cations used to treat climacteric disorder include tokisha-
kuyakusan, TJ-24, and keishibukuryogan, and of these, TJ-
24 is most widely used as a formulation of dry extract
granules based on the preparation listed in the Wazai
Kyokuho, the classical pharmacopeia of Kampo medicine.
Clinical studies reported that TJ-24 improved neuropsy-
chiatric symptoms [6, 7], vasomotor symptoms [6], and
sleep disturbance [7] in patients with climacteric disorder. In
basic studies, kamishoyosan was revealed to exert an an-
xiolytic effect through stimulation of the c-aminobutyric
acid A-benzodiazepine receptor in male mice [15] and so-
cially isolated ovariectomized rats [16]. Moreover,
kamishoyosan was demonstrated to exert an antidepressive
effect through the 5-HT1A receptor and PKA-CREB-BDNF
signaling in postmenopausal depression model mice [17].
However, few previous clinical studies conducted objective
investigations from the perspective of evidence-based
medicine. In a previous double-blind, randomized trial, we
observed a major placebo effect, resulting in no significant





































Figure 3: *e distribution of score changes for excitability and irritability.
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placebo [10]. In planning the present study, therefore, a
study design was employed to investigate the actual effect of
TJ-24. Climacteric disorder encompasses numerous symp-
toms and complaints, and previous randomized, controlled
trials mainly focused on hot flashes or secondary depressive
symptoms that may result from the presence of these
symptoms and complaints. Because the results of previous
open trials suggested that TJ-24 improves psychiatric
symptoms, particularly irritability and insomnia, excitability
and irritability comprised the primary outcome. *e study
design also included a run-in period to exclude women
particularly susceptible to the placebo effect, aiming to re-
duce the impact of this effect. *e intention was to ascertain
the effect of TJ-24 by targeting placebo nonresponders.
Although TJ-24 significantly improved the score for
excitability and irritability, the primary outcome, in the NR
group, in line with our previous study, there was no sig-
nificant difference in the score change between the TJ-24 and
the placebo arms. However, an assessment of the proportion
of participants whose score improved by ≥3 points revealed a
significantly higher rate in the TJ-24 arm, suggesting that TJ-
24 may have had an effect and supporting the impression of
efficacy observed in clinical practice. Concerning safety, no
worrisome severe adverse drug reactions or adverse events
were observed, and there was no difference in the incidence
of adverse drug reactions or adverse events between the
study arms, indicating that TJ-24 is safe for use.
In the subgroup analyses, TJ-24 significantly reduced the
score for excitability and irritability in premenopausal
women. Hidaka et al. reported that TJ-24 is effective against
psychiatric symptoms [6], and mental factors are known to
play a major role in the perimenopausal period. In fact, it is
well known that depression causes the appearance of
menopausal symptoms [18]. Women with no previous
history of depression are reportedly at higher risk of peri-
menopausal depression prior to menopause, and this risk
decreases after menopause [19]. In clinical practice, it is
difficult to provide HT to premenopausal women, and the
fact that TJ-24 improves excitability and irritability in these
women is one advantage of the medicine. *is symptom is
also comparatively common in Japanese women [20]. *is
suggests that TJ-24 may help improve QOL as a nonhor-
monal treatment option for perimenopausal women who
cannot be prescribed HT or who do not wish to take it.
Regarding sweating and hot flashes, the score change among
postmenopausal women was larger in the placebo group
than in the TJ-24 group, suggesting that the change was
likely a placebo effect. In addition, in this study, we selected
womenwith available excitability and irritability score and at
least one menopausal symptom (hot flashes, sweating, dif-
ficulty in sleeping, and waking up at night). *erefore, the
baseline sweating and hot flash score was not constant at
baseline, and thus, we considered that the finding was a
possible incidental result of statistical analysis.
*e strength of the placebo effect may be attributable to
the following reasons. *e first is the problem of the criteria
for placebo responders. In the present study, participants
whose excitability and irritability scores improved by ≥3
points following the 4-week run-in period were considered
placebo responders. *e rationale for this was that placebo
use is believed to improve menopausal symptoms by ap-
proximately 34% [9, 21], and thus, a score change of ≥3
points, corresponding to a ≥30% improvement, was con-
sidered to indicate response. In this study, 24.5% of patients
were included in the R group, a somewhat low proportion,
suggesting that the NR group may also have included some
responders. In addition, it is possible that the placebo effect
could have been more completely eliminated by setting the
cutoff at ≥2 points. However, if a cutoff of ≥2 points had been
used, the NR group would only have included 56.5% of
participants, and securing sufficient numbers for this group
would have been an issue.
Second, it is possible that the 4-week run-in period may
have been too short, and the placebo effect may have been
eliminated in a longer period. *is point was repeatedly
considered before starting this study, but from an ethical
standpoint, a run-in period exceeding 4weeks would have
been inappropriate.
A third possibility is that the participants may have
identified the placebo. *ey were not informed that they
were taking a placebo during the run-in period, and they
may have realized that their medication had changed after
randomization. *e severity of symptoms was also assessed
subjectively by the participants themselves rather than by an
objective index, and when the same questionnaire is used,
there is a tendency to indicate that improvements have
occurred.
Fourth, the participants included premenopausal
women. Premenopausal and postmenopausal women may
have different mechanisms of onset for menopausal
symptoms. *e hormone levels in these women are in-
consistent, and individual differences in factors other than
hormone levels may also have had an effect. In fact, in terms
of the clustering of menopausal symptoms, they are believed
to stabilize after menopause [22].
*e fifth issue is seasonal changes. Menopausal symp-
toms have been reported to change with the seasons [23],
and the difference between the placebo and actual drug may
have narrowed at some points. However, in the present
study, no adjustment was made for the timing of the
investigation.
*e study also had several other limitations. *e first
limitation was the dosage. Increasing the dose might pos-
sibly have resulted in a stronger effect. However, other
studies of Kampo medication have found that increasing the
dose did not influence outcomes [9], and in the present
study, the normal dose under Japanese approval conditions
was used. *e second limitation was the sample size. As
mentioned previously, increasing the number of participants
might have weakened the impact of the placebo effect, and it
may be necessary to reconsider the sample size. However,
recruiting participants is also difficult. *e third limitation
was the administration period. Although there is justifica-
tion for extending the protocol, particularly the run-in
period, this might pose an ethical problem.
In this multicenter, randomized, double-blind, placebo-
controlled trial of TJ-24 for the treatment of climacteric
disorder, no difference was observed in the score for
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excitability and irritability between the TJ-24 and placebo
arms because of a placebo effect. However, given that the
proportion of participants whose score improved by ≥3
points was significantly larger in the TJ-24 arm, the safety
results were good, and the excitability and irritability score
improved significantly in premenopausal women, TJ-24may
represent an option for nonhormonal treatment. Further
studies are warranted to further examine these issues.
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